Long-term natural history of neurofibromatosis Type 2–associated intracranial tumors

Clinical article

Restricted access

Object

Neurofibromatosis Type 2 (NF2) is a heritable tumor predisposition syndrome that leads to the development of multiple intracranial tumors, including meningiomas and schwannomas. Because the natural history of these tumors has not been determined, their optimal management has not been established. To define the natural history of NF2-associated intracranial tumors and to optimize management strategies, the authors evaluated long-term clinical and radiographic data in patients with NF2.

Methods

Consecutive NF2 patients with a minimum of 4 years of serial clinical and MRI follow-up were analyzed.

Results

Seventeen patients, 9 males and 8 females, were included in this analysis (mean follow-up 9.5 ± 4.8 years, range 4.0–20.7 years). The mean age at initial evaluation was 33.2 ± 15.5 years (range 12.3–57.6 years). Patients harbored 182 intracranial neoplasms, 164 of which were assessable for growth rate analysis (18 vestibular schwannomas [VSs], 11 nonvestibular cranial nerve [CN] schwannomas, and 135 meningiomas) and 152 of which were assessable for growth pattern analysis (15 VSs, 9 nonvestibular CN schwannomas, and 128 meningiomas). New tumors developed in patients over the course of the imaging follow-up: 66 meningiomas, 2 VSs, and 2 nonvestibular CN schwannomas. Overall, 45 tumors (29.6%) exhibited linear growth, 17 tumors (11.2%) exhibited exponential growth, and 90 tumors (59.2%) displayed a saltatory growth pattern characterized by alternating periods of growth and quiescence (mean quiescent period 2.3 ± 2.1 years, range 0.4–11.7 years). Further, the saltatory pattern was the most frequently identified growth pattern for each tumor type: meningiomas 60.9%, VSs 46.7%, and nonvestibular schwannoma 55.6%. A younger age at the onset of NF2-related symptoms (p = 0.01) and female sex (p = 0.05) were associated with an increased growth rate in meningiomas. The identification of saltatory growth in meningiomas increased with the duration of follow-up (p = 0.01).

Conclusions

Neurofibromatosis Type 2–associated intracranial tumors most frequently demonstrated a saltatory growth pattern. Because new tumors can develop in NF2 patients over their lifetime and because radiographic progression and symptom formation are unpredictable, resection may be best reserved for symptom-producing tumors. Moreover, establishing the efficacy of nonsurgical therapeutic interventions must be based on long-term follow-up (several years).

Abbreviations used in this paper:CN = cranial nerve; KPS = Karnofsky Performance Scale; NF2 = neurofibromatosis Type 2; SRS = stereotactic radiosurgery; VHL = von Hippel-Lindau; VS = vestibular schwannoma.
Article Information

Contributor Notes

Address correspondence to: Ashok R. Asthagiri, M.D., Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 10, Room 3D20, Bethesda, Maryland 20892-1414. email: asthagiria@ninds.nih.gov.Please include this information when citing this paper: published online April 13, 2012; DOI: 10.3171/2012.3.JNS111649.

© AANS, except where prohibited by US copyright law.

Headings
References
  • 1

    Abaza MMMakariou EArmstrong MLalwani AK: Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2. Laryngoscope 106:6946991996

    • Search Google Scholar
    • Export Citation
  • 2

    Ammerman JMLonser RRDambrosia JButman JAOldfield EH: Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 105:2482552006

    • Search Google Scholar
    • Export Citation
  • 3

    Asthagiri ARMehta GUZach LLi XButman JACamphausen KA: Prospective evaluation of radiosurgery for hemangioblastomas in von Hippel-Lindau disease. Neurooncol 12:80862010

    • Search Google Scholar
    • Export Citation
  • 4

    Asthagiri ARParry DMButman JAKim HJTsilou ETZhuang Z: Neurofibromatosis type 2. Lancet 373:197419862009

  • 5

    Baser MEFriedman JMAeschliman DJoe HWallace AJRamsden RT: Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 71:7157232002

    • Search Google Scholar
    • Export Citation
  • 6

    Baser MEFriedman JMWallace AJRamsden RTJoe HEvans DGR: Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:175917652002

    • Search Google Scholar
    • Export Citation
  • 7

    Baser MEMakariou EVParry DM: Predictors of vestibular schwannoma growth in patients with neurofibromatosis Type 2. J Neurosurg 96:2172222002

    • Search Google Scholar
    • Export Citation
  • 8

    Baser MEMautner VFParry DMEvans DG: Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2. J Med Genet 42:9039062005

    • Search Google Scholar
    • Export Citation
  • 9

    Blaauw GBlankenstein MALamberts SWJ: Sex steroid receptors in human meningiomas. Acta Neurochir (Wien) 79:42471986

  • 10

    Evans DGKalamarides MHunter-Schaedle KBlakeley JAllen JBabovic-Vuskanovic D: Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res 15:503250392009

    • Search Google Scholar
    • Export Citation
  • 11

    Evans DGRHuson SMDonnai DNeary WBlair VNewton V: A clinical study of type 2 neurofibromatosis. Q J Med 84:6036181992

  • 12

    Evans DGRMoran AKing ASaeed SGurusinghe NRamsden R: Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93972005

    • Search Google Scholar
    • Export Citation
  • 13

    Fisher LMDoherty JKLev MHSlattery WH III: Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2. Otol Neurotol 28:108310902007

    • Search Google Scholar
    • Export Citation
  • 14

    Gijtenbeek JMMGabreëls-Festen AALammens MZwarts MJvan Engelen BG: Mononeuropathy multiplex as the initial manifestation of neurofibromatosis type 2. Neurology 56:176617682001

    • Search Google Scholar
    • Export Citation
  • 15

    Hagel CLindenau MLamszus KKluwe LStavrou DMautner VF: Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. Acta Neuropathol 104:1791872002

    • Search Google Scholar
    • Export Citation
  • 16

    Harris GJPlotkin SRMaccollin MBhat SUrban TLev MH: Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery 62:131413202008

    • Search Google Scholar
    • Export Citation
  • 17

    Hashiba THashimoto NIzumoto SSuzuki TKagawa NMaruno M: Serial volumetric assessment of the natural history and growth pattern of incidentally discovered meningiomas. Clinical article. J Neurosurg 110:6756842009

    • Search Google Scholar
    • Export Citation
  • 18

    Hsu DWEfird JTHedley-Whyte ET: Progesterone and estrogen receptors in meningiomas: prognostic considerations. J Neurosurg 86:1131201997

    • Search Google Scholar
    • Export Citation
  • 19

    Ito ESaito KYatsuya HNagatani TOtsuka G: Factors predicting growth of vestibular schwannoma in neurofibromatosis type 2. Neurosurg Rev 32:4254332009

    • Search Google Scholar
    • Export Citation
  • 20

    Kida YKobayashi TTanaka TMori Y: Radiosurgery for bilateral neurinomas associated with neurofibromatosis type 2. Surg Neurol 53:3833902000

    • Search Google Scholar
    • Export Citation
  • 21

    Kondziolka DLunsford LDMcLaughlin MRFlickinger JC: Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med 339:142614331998

    • Search Google Scholar
    • Export Citation
  • 22

    Lundin PPedersen F: Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16:5195281992

  • 23

    Mathieu DKondziolka DFlickinger JCNiranjan AWilliamson RMartin JJ: Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates. Neurosurgery 60:4604702007

    • Search Google Scholar
    • Export Citation
  • 24

    Mautner VFBaser METhakkar SDFeigen UMFriedman JMKluwe L: Vestibular schwannoma growth in patients with neurofibromatosis Type 2: a longitudinal study. J Neurosurg 96:2232282002

    • Search Google Scholar
    • Export Citation
  • 25

    Mautner VFLindenau MBaser MEHazim WTatagiba MHaase W: The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 38:8808861996

    • Search Google Scholar
    • Export Citation
  • 26

    Maxwell MGalanopoulos TNeville-Golden JAntoniades HN: Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 78:4564621993

    • Search Google Scholar
    • Export Citation
  • 27

    Nakasu SFukami TNakajima MWatanabe KIchikawa MMatsuda M: Growth pattern changes of meningiomas: longterm analysis. Neurosurgery 56:9469552005

    • Search Google Scholar
    • Export Citation
  • 28

    Olivero WCLister JRElwood PW: The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg 83:2222241995

    • Search Google Scholar
    • Export Citation
  • 29

    Parry DMEldridge RKaiser-Kupfer MIBouzas EAPikus APatronas N: Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 52:4504611994

    • Search Google Scholar
    • Export Citation
  • 30

    Perrot-Applanat MGroyer-Picard MTKujas M: Immunocytochemical study of progesterone receptor in human meningioma. Acta Neurochir (Wien) 115:20301992

    • Search Google Scholar
    • Export Citation
  • 31

    Perry AGiannini CRaghavan RScheithauer BWBanerjee RMargraf L: Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 60:99410032001

    • Search Google Scholar
    • Export Citation
  • 32

    Rouleau GAMerel PLutchman MSanson MZucman JMarineau C: Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:5155211993

    • Search Google Scholar
    • Export Citation
  • 33

    Rowe JRadatz MKemeny A: Radiosurgery for type II neurofibromatosis. Prog Neurol Surg 21:1761822008

  • 34

    Rowe JGRadatz MWWalton LSoanes TRodgers JKemeny AA: Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. J Neurol Neurosurg Psychiatry 74:128812932003

    • Search Google Scholar
    • Export Citation
  • 35

    Slattery WHLev MHFisher LMConnell SSIqbal ZGo JL: MRI evaluation of neurofibromatosis 2 patients: a standardized approach for accuracy in interpretation. Otol Neurotol 26:7337402005

    • Search Google Scholar
    • Export Citation
  • 36

    Slattery WH IIIFisher LMIqbal ZOppenhiemer M: Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol 25:8118172004

    • Search Google Scholar
    • Export Citation
  • 37

    Trofatter JAMacCollin MMRutter JLMurrell JRDuyao MPParry DM: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 75:8261993

    • Search Google Scholar
    • Export Citation
  • 38

    Yoneoka YFujii YTanaka R: Growth of incidental meningiomas. Acta Neurochir (Wien) 142:5075112000

TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 198 193 10
Full Text Views 204 121 2
PDF Downloads 118 60 1
EPUB Downloads 0 0 0
PubMed
Google Scholar